Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660701 | 0.77 | IDO1 (0.33) | IDO1AKR1B1AGXT | |
| SCHEMBL26586522 | 0.77 | IDO1 (0.33) | IDO1AKR1B1AGXT | |
| SCHEMBL15012263 | 0.77 | SLC6A4 (0.37) | IDO1AKR1B1SLC6A4AGXTMAP2K2 | |
| SCHEMBL30028568 | 0.77 | SLC6A4 (0.37) | IDO1AKR1B1SLC6A4AGXTMAP2K2 | |
| SCHEMBL30028529 | 0.77 | IDO1 (0.33) | IDO1AKR1B1AGXT | |
| SCHEMBL10487847 | 0.77 | LOXL2 (0.42) | IDO1AKR1B1SLC6A4AGXTMAP2K2 | |
| SCHEMBL257063 | 0.77 | AKR1B1 (0.35) | IDO1AKR1B1SLC6A4AGXTMAP2K2 | |
| SCHEMBL12647189 | 0.76 | IDO1 (0.54) | IDO1AGXT | |
| SCHEMBL12069846 | 0.74 | IDO1 (0.33) | IDO1AGXT | |
| SCHEMBL14392749 | 0.74 | IDO1 (0.33) | IDO1AKR1B1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | IDO1 3153/4885AKR1B1 2246/4885SLC6A4 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.